← Back to Analyst Consensus 
IRMD Buy
IRADIMED CORP
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 22, 2026 | Needham | initiate | — → Hold | — | 50% |
| Apr 2, 2026 | Freedom Broker | initiate | — → Buy | — | 59% |
| Feb 14, 2025 | Roth MKM | reiterate | Buy → Buy | $72 | 52% |
| Aug 2, 2024 | Roth MKM | maintain | Buy → Buy | $60 | 52% |
| Aug 2, 2021 | Roth Capital | maintain | — → Buy | $36 | 53% |
| Jul 31, 2017 | Roth Capital | upgrade | Neutral → Buy | $0 | 53% |
| Oct 5, 2016 | Roth Capital | downgrade | Buy → Neutral | $0 | 53% |
| Apr 4, 2016 | Roth Capital | maintain | — → Buy | $25 | 53% |
| Jun 16, 2015 | Roth Capital | maintain | — → Buy | $23 | 53% |
| Aug 11, 2014 | Roth Capital | initiate | — | $14 | 53% |
Price Target Trend
Apr 1, 2026 Latest: $118 Oct 24, 2026
EPS Estimates
0y $2.11
Lo: $2.09 Hi: $2.16
3 analysts ▲2
+1y $2.45
Lo: $2.40 Hi: $2.54
3 analysts ▲2
+1q $0.63
Lo: $0.61 Hi: $0.66
3 analysts ▲2
0q $0.55
Lo: $0.54 Hi: $0.56
3 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days